ID   SIR3_HUMAN              Reviewed;         399 AA.
AC   Q9NTG7; B7Z5U6; Q9Y6E8;
DT   31-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2003, sequence version 2.
DT   10-MAY-2017, entry version 145.
DE   RecName: Full=NAD-dependent protein deacetylase sirtuin-3, mitochondrial;
DE            Short=hSIRT3;
DE            EC=3.5.1.-;
DE   AltName: Full=Regulatory protein SIR2 homolog 3;
DE   AltName: Full=SIR2-like protein 3;
DE   Flags: Precursor;
GN   Name=SIRT3; Synonyms=SIR2L3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=10381378; DOI=10.1006/bbrc.1999.0897;
RA   Frye R.A.;
RT   "Characterization of five human cDNAs with homology to the yeast SIR2
RT   gene: Sir2-like proteins (sirtuins) metabolize NAD and may have
RT   protein ADP-ribosyltransferase activity.";
RL   Biochem. Biophys. Res. Commun. 260:273-279(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 282-399 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   ENZYME ACTIVITY, SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING BY MPP,
RP   AND MUTAGENESIS OF ARG-7; ARG-13; ARG-17; ARG-21; 99-ARG-ARG-100;
RP   ASN-229 AND HIS-248.
RX   PubMed=12186850; DOI=10.1083/jcb.200205057;
RA   Schwer B., North B.J., Frye R.A., Ott M., Verdin E.;
RT   "The human silent information regulator (Sir)2 homologue hSIRT3 is a
RT   mitochondrial nicotinamide adenine dinucleotide-dependent
RT   deacetylase.";
RL   J. Cell Biol. 158:647-657(2002).
RN   [7]
RP   ENZYME ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12374852; DOI=10.1073/pnas.222538099;
RA   Onyango P., Celic I., McCaffery J.M., Boeke J.D., Feinberg A.P.;
RT   "SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase
RT   localized to mitochondria.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:13653-13658(2002).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16079181; DOI=10.1091/mbc.E05-01-0033;
RA   Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I.;
RT   "Evolutionarily conserved and nonconserved cellular localizations and
RT   functions of human SIRT proteins.";
RL   Mol. Biol. Cell 16:4623-4635(2005).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF HIS-248, AND INTERACTION
RP   WITH ACSS1.
RX   PubMed=16788062; DOI=10.1073/pnas.0603968103;
RA   Schwer B., Bunkenborg J., Verdin R.O., Andersen J.S., Verdin E.;
RT   "Reversible lysine acetylation controls the activity of the
RT   mitochondrial enzyme acetyl-CoA synthetase 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10224-10229(2006).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18215119; DOI=10.1042/BJ20071624;
RA   Cooper H.M., Spelbrink J.N.;
RT   "The human SIRT3 protein deacetylase is exclusively mitochondrial.";
RL   Biochem. J. 411:279-285(2008).
RN   [11]
RP   FUNCTION.
RX   PubMed=18680753; DOI=10.1016/j.jmb.2008.07.048;
RA   Schlicker C., Gertz M., Papatheodorou P., Kachholz B., Becker C.F.W.,
RA   Steegborn C.;
RT   "Substrates and regulation mechanisms for the human mitochondrial
RT   sirtuins Sirt3 and Sirt5.";
RL   J. Mol. Biol. 382:790-801(2008).
RN   [12]
RP   MUTAGENESIS OF HIS-248, FUNCTION, AND INTERACTION WITH NDUFA9.
RX   PubMed=18794531; DOI=10.1073/pnas.0803790105;
RA   Ahn B.-H., Kim H.-S., Song S., Lee I.H., Liu J., Vassilopoulos A.,
RA   Deng C.-X., Finkel T.;
RT   "A role for the mitochondrial deacetylase Sirt3 in regulating energy
RT   homeostasis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:14447-14452(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   FUNCTION.
RX   PubMed=24252090; DOI=10.1089/ars.2013.5420;
RA   Vassilopoulos A., Pennington D.J., Andresson T., Rees D., Fearnley I.,
RA   Ham A., Yan Y., Flynn C.R., Jones K., Kim H.S., Deng C., Walker J.,
RA   Gius D.;
RT   "SIRT3 deacetylates ATP synthase F1 complex proteins in response to
RT   nutrient and exercise-induced stress.";
RL   Antioxid. Redox Signal. 21:551-564(2014).
RN   [15]
RP   FUNCTION.
RX   PubMed=24121500; DOI=10.1074/jbc.M113.510354;
RA   Bharathi S.S., Zhang Y., Mohsen A.W., Uppala R., Balasubramani M.,
RA   Schreiber E., Uechi G., Beck M.E., Rardin M.J., Vockley J., Verdin E.,
RA   Gibson B.W., Hirschey M.D., Goetzman E.S.;
RT   "SIRT3 regulates long-chain acyl-coA dehydrogenase by deacetylating
RT   conserved lysines near the active site.";
RL   J. Biol. Chem. 288:33837-33847(2013).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 118-399 IN COMPLEX WITH ZINC
RP   IONS AND ACSS1, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   NAD-BINDING.
RX   PubMed=19535340; DOI=10.1074/jbc.M109.014928;
RA   Jin L., Wei W., Jiang Y., Peng H., Cai J., Mao C., Dai H., Choy W.,
RA   Bemis J.E., Jirousek M.R., Milne J.C., Westphal C.H., Perni R.B.;
RT   "Crystal structures of human SIRT3 displaying substrate-induced
RT   conformational changes.";
RL   J. Biol. Chem. 284:24394-24405(2009).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 116-399 IN COMPLEX WITH
RP   INHIBITOR, NAD-BINDING SITES, AND ZINC-BINDING SITES.
RX   PubMed=23897466; DOI=10.1107/S0907444913015448;
RA   Nguyen G.T., Schaefer S., Gertz M., Weyand M., Steegborn C.;
RT   "Structures of human sirtuin 3 complexes with ADP-ribose and with
RT   carba-NAD+ and SRT1720: binding details and inhibition mechanism.";
RL   Acta Crystallogr. D 69:1423-1432(2013).
CC   -!- FUNCTION: NAD-dependent protein deacetylase. Activates or
CC       deactivates mitochondrial target proteins by deacetylating key
CC       lysine residues. Known targets include ACSS1, IDH, GDH, SOD2,
CC       PDHA1, LCAD, SDHA and the ATP synthase subunit ATP5O. Contributes
CC       to the regulation of the cellular energy metabolism. Important for
CC       regulating tissue-specific ATP levels.
CC       {ECO:0000269|PubMed:16788062, ECO:0000269|PubMed:18680753,
CC       ECO:0000269|PubMed:18794531, ECO:0000269|PubMed:19535340,
CC       ECO:0000269|PubMed:24121500, ECO:0000269|PubMed:24252090}.
CC   -!- CATALYTIC ACTIVITY: NAD(+) + an acetylprotein = nicotinamide + O-
CC       acetyl-ADP-ribose + a protein. {ECO:0000255|PROSITE-
CC       ProRule:PRU00236, ECO:0000269|PubMed:12186850,
CC       ECO:0000269|PubMed:12374852, ECO:0000269|PubMed:16788062}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=600 uM for NAD {ECO:0000269|PubMed:19535340};
CC   -!- SUBUNIT: Interacts with NDUFA9, ACSS1, IDH2 and GDH.
CC       {ECO:0000269|PubMed:16788062, ECO:0000269|PubMed:18794531,
CC       ECO:0000269|PubMed:19535340, ECO:0000269|PubMed:23897466}.
CC   -!- INTERACTION:
CC       P25705:ATP5A1; NbExp=2; IntAct=EBI-724621, EBI-351437;
CC       O60313:OPA1; NbExp=3; IntAct=EBI-724621, EBI-1054131;
CC       Q13309:SKP2; NbExp=5; IntAct=EBI-724621, EBI-456291;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix
CC       {ECO:0000269|PubMed:12186850, ECO:0000269|PubMed:12374852,
CC       ECO:0000269|PubMed:16079181, ECO:0000269|PubMed:18215119}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NTG7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NTG7-2; Sequence=VSP_043792;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:10381378, ECO:0000269|PubMed:12374852}.
CC   -!- PTM: Processed by mitochondrial processing peptidase (MPP) to give
CC       a 28 kDa product. Such processing is probably essential for its
CC       enzymatic activity. {ECO:0000269|PubMed:12186850}.
CC   -!- MISCELLANEOUS: Has some ability to deacetylate histones in vitro,
CC       but seeing its subcellular location, this is unlikely in vivo.
CC   -!- SIMILARITY: Belongs to the sirtuin family. Class I subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF083108; AAD40851.1; -; mRNA.
DR   EMBL; AK299438; BAH13032.1; -; mRNA.
DR   EMBL; AC136475; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001042; AAH01042.1; -; mRNA.
DR   EMBL; AL137276; CAB70674.1; -; mRNA.
DR   CCDS; CCDS53590.1; -. [Q9NTG7-2]
DR   CCDS; CCDS7691.1; -. [Q9NTG7-1]
DR   PIR; T46348; T46348.
DR   RefSeq; NP_001017524.1; NM_001017524.2. [Q9NTG7-2]
DR   RefSeq; NP_036371.1; NM_012239.5. [Q9NTG7-1]
DR   RefSeq; XP_016872919.1; XM_017017430.1. [Q9NTG7-2]
DR   UniGene; Hs.716456; -.
DR   PDB; 3GLR; X-ray; 1.80 A; A=118-399.
DR   PDB; 3GLS; X-ray; 2.70 A; A/B/C/D/E/F=118-399.
DR   PDB; 3GLT; X-ray; 2.10 A; A=118-399.
DR   PDB; 3GLU; X-ray; 2.50 A; A=118-399.
DR   PDB; 4BN4; X-ray; 1.30 A; A=116-399.
DR   PDB; 4BN5; X-ray; 3.25 A; A/B/C/D/E/F/G/H/I/J/K/L=119-399.
DR   PDB; 4BV3; X-ray; 2.00 A; A=116-399.
DR   PDB; 4BVB; X-ray; 2.00 A; A=116-399.
DR   PDB; 4BVE; X-ray; 2.05 A; A=116-399.
DR   PDB; 4BVF; X-ray; 2.70 A; A=116-399.
DR   PDB; 4BVG; X-ray; 2.50 A; A=116-399.
DR   PDB; 4BVH; X-ray; 1.90 A; A/B/C=116-399.
DR   PDB; 4C78; X-ray; 2.00 A; A=116-399.
DR   PDB; 4C7B; X-ray; 2.10 A; A=117-399.
DR   PDB; 4FVT; X-ray; 2.47 A; A=122-395.
DR   PDB; 4FZ3; X-ray; 2.10 A; A=118-399.
DR   PDB; 4HD8; X-ray; 2.30 A; A=116-399.
DR   PDB; 4JSR; X-ray; 1.70 A; A=118-399.
DR   PDB; 4JT8; X-ray; 2.26 A; A=118-399.
DR   PDB; 4JT9; X-ray; 2.24 A; A=118-399.
DR   PDB; 4O8Z; X-ray; 2.00 A; A=116-399.
DR   PDB; 4V1C; X-ray; 2.95 A; A/B/E/G/I/K=121-394.
DR   PDB; 5BWN; X-ray; 1.94 A; A=118-399.
DR   PDB; 5BWO; X-ray; 2.38 A; A=118-399.
DR   PDB; 5D7N; X-ray; 1.83 A; A/B/C/D/E/F=118-395.
DR   PDBsum; 3GLR; -.
DR   PDBsum; 3GLS; -.
DR   PDBsum; 3GLT; -.
DR   PDBsum; 3GLU; -.
DR   PDBsum; 4BN4; -.
DR   PDBsum; 4BN5; -.
DR   PDBsum; 4BV3; -.
DR   PDBsum; 4BVB; -.
DR   PDBsum; 4BVE; -.
DR   PDBsum; 4BVF; -.
DR   PDBsum; 4BVG; -.
DR   PDBsum; 4BVH; -.
DR   PDBsum; 4C78; -.
DR   PDBsum; 4C7B; -.
DR   PDBsum; 4FVT; -.
DR   PDBsum; 4FZ3; -.
DR   PDBsum; 4HD8; -.
DR   PDBsum; 4JSR; -.
DR   PDBsum; 4JT8; -.
DR   PDBsum; 4JT9; -.
DR   PDBsum; 4O8Z; -.
DR   PDBsum; 4V1C; -.
DR   PDBsum; 5BWN; -.
DR   PDBsum; 5BWO; -.
DR   PDBsum; 5D7N; -.
DR   ProteinModelPortal; Q9NTG7; -.
DR   SMR; Q9NTG7; -.
DR   BioGrid; 116982; 47.
DR   DIP; DIP-46861N; -.
DR   IntAct; Q9NTG7; 29.
DR   MINT; MINT-4540133; -.
DR   STRING; 9606.ENSP00000372191; -.
DR   BindingDB; Q9NTG7; -.
DR   ChEMBL; CHEMBL4461; -.
DR   DrugBank; DB02059; Adenosine-5-Diphosphoribose.
DR   GuidetoPHARMACOLOGY; 2709; -.
DR   iPTMnet; Q9NTG7; -.
DR   PhosphoSitePlus; Q9NTG7; -.
DR   BioMuta; SIRT3; -.
DR   DMDM; 38258651; -.
DR   EPD; Q9NTG7; -.
DR   MaxQB; Q9NTG7; -.
DR   PaxDb; Q9NTG7; -.
DR   PeptideAtlas; Q9NTG7; -.
DR   PRIDE; Q9NTG7; -.
DR   Ensembl; ENST00000382743; ENSP00000372191; ENSG00000142082. [Q9NTG7-1]
DR   Ensembl; ENST00000529382; ENSP00000437216; ENSG00000142082. [Q9NTG7-2]
DR   GeneID; 23410; -.
DR   KEGG; hsa:23410; -.
DR   UCSC; uc001lok.5; human. [Q9NTG7-1]
DR   CTD; 23410; -.
DR   DisGeNET; 23410; -.
DR   GeneCards; SIRT3; -.
DR   HGNC; HGNC:14931; SIRT3.
DR   HPA; CAB037142; -.
DR   HPA; HPA026809; -.
DR   MIM; 604481; gene.
DR   neXtProt; NX_Q9NTG7; -.
DR   OpenTargets; ENSG00000142082; -.
DR   PharmGKB; PA37936; -.
DR   eggNOG; KOG2682; Eukaryota.
DR   eggNOG; COG0846; LUCA.
DR   GeneTree; ENSGT00870000136486; -.
DR   HOVERGEN; HBG057095; -.
DR   InParanoid; Q9NTG7; -.
DR   KO; K11413; -.
DR   OMA; CTGIVKP; -.
DR   OrthoDB; EOG091G07CT; -.
DR   PhylomeDB; Q9NTG7; -.
DR   TreeFam; TF106181; -.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   SIGNOR; Q9NTG7; -.
DR   ChiTaRS; SIRT3; human.
DR   EvolutionaryTrace; Q9NTG7; -.
DR   GeneWiki; SIRT3; -.
DR   GenomeRNAi; 23410; -.
DR   PRO; PR:Q9NTG7; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000142082; -.
DR   CleanEx; HS_SIRT3; -.
DR   ExpressionAtlas; Q9NTG7; baseline and differential.
DR   Genevisible; Q9NTG7; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IEA:Ensembl.
DR   GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003950; F:NAD+ ADP-ribosyltransferase activity; TAS:ProtInc.
DR   GO; GO:0070403; F:NAD+ binding; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0009060; P:aerobic respiration; IMP:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007005; P:mitochondrion organization; TAS:Reactome.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0034983; P:peptidyl-lysine deacetylation; IMP:UniProtKB.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0006471; P:protein ADP-ribosylation; TAS:ProtInc.
DR   GO; GO:0006476; P:protein deacetylation; IDA:UniProtKB.
DR   Gene3D; 3.40.50.1220; -; 1.
DR   InterPro; IPR029035; DHS-like_NAD/FAD-binding_dom.
DR   InterPro; IPR003000; Sirtuin.
DR   InterPro; IPR026590; Ssirtuin_cat_dom.
DR   Pfam; PF02146; SIR2; 1.
DR   SUPFAM; SSF52467; SSF52467; 1.
DR   PROSITE; PS50305; SIRTUIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Hydrolase;
KW   Metal-binding; Mitochondrion; NAD; Polymorphism; Reference proteome;
KW   Transit peptide; Zinc.
FT   TRANSIT       1      ?       Mitochondrion. {ECO:0000255}.
FT   CHAIN         ?    399       NAD-dependent protein deacetylase
FT                                sirtuin-3, mitochondrial.
FT                                /FTId=PRO_0000032612.
FT   DOMAIN      126    382       Deacetylase sirtuin-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00236}.
FT   NP_BIND     145    165       NAD.
FT   NP_BIND     228    231       NAD.
FT   NP_BIND     319    321       NAD.
FT   NP_BIND     344    346       NAD.
FT   ACT_SITE    248    248       Proton acceptor.
FT   METAL       256    256       Zinc.
FT   METAL       259    259       Zinc.
FT   METAL       280    280       Zinc.
FT   METAL       283    283       Zinc.
FT   BINDING     366    366       NAD; via amide nitrogen. {ECO:0000250}.
FT   MOD_RES     122    122       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q8R104}.
FT   VAR_SEQ       1    142       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043792.
FT   VARIANT      80     80       R -> W (in dbSNP:rs28365927).
FT                                /FTId=VAR_051977.
FT   VARIANT     208    208       V -> I (in dbSNP:rs11246020).
FT                                /FTId=VAR_051978.
FT   VARIANT     369    369       G -> S (in dbSNP:rs3020901).
FT                                /FTId=VAR_051979.
FT   MUTAGEN       7      7       R->G,Q: Suppresses targeting to
FT                                mitochondrion; when associated with G-13
FT                                or Q-13. {ECO:0000269|PubMed:12186850}.
FT   MUTAGEN      13     13       R->G,Q: Suppresses targeting to
FT                                mitochondrion; when associated with G-7
FT                                or Q-7. {ECO:0000269|PubMed:12186850}.
FT   MUTAGEN      17     17       R->G,Q: Reduces targeting to
FT                                mitochondrion; when associated with G-21
FT                                or Q-21. {ECO:0000269|PubMed:12186850}.
FT   MUTAGEN      21     21       R->G,Q: Reduces targeting to
FT                                mitochondrion; when associated with G-17
FT                                or Q-17. {ECO:0000269|PubMed:12186850}.
FT   MUTAGEN      99    100       RR->GG: Abolishes processing by MPP (in
FT                                vitro). {ECO:0000269|PubMed:12186850}.
FT   MUTAGEN     229    229       N->A: Loss of function.
FT                                {ECO:0000269|PubMed:12186850}.
FT   MUTAGEN     248    248       H->Y: Loss of function.
FT                                {ECO:0000269|PubMed:12186850,
FT                                ECO:0000269|PubMed:16788062,
FT                                ECO:0000269|PubMed:18794531}.
FT   HELIX       125    133       {ECO:0000244|PDB:4BN4}.
FT   TURN        134    136       {ECO:0000244|PDB:4C7B}.
FT   STRAND      140    144       {ECO:0000244|PDB:4BN4}.
FT   HELIX       146    152       {ECO:0000244|PDB:4BN4}.
FT   STRAND      157    159       {ECO:0000244|PDB:4BN4}.
FT   TURN        160    162       {ECO:0000244|PDB:4BN4}.
FT   HELIX       164    168       {ECO:0000244|PDB:4BN4}.
FT   STRAND      171    175       {ECO:0000244|PDB:4BN4}.
FT   HELIX       176    180       {ECO:0000244|PDB:4BN4}.
FT   HELIX       182    187       {ECO:0000244|PDB:4BN4}.
FT   HELIX       190    199       {ECO:0000244|PDB:4BN4}.
FT   STRAND      201    203       {ECO:0000244|PDB:4BV3}.
FT   HELIX       208    218       {ECO:0000244|PDB:4BN4}.
FT   STRAND      222    227       {ECO:0000244|PDB:4BN4}.
FT   HELIX       233    236       {ECO:0000244|PDB:4BN4}.
FT   HELIX       241    243       {ECO:0000244|PDB:4BN4}.
FT   STRAND      244    246       {ECO:0000244|PDB:4BN4}.
FT   STRAND      249    256       {ECO:0000244|PDB:4BN4}.
FT   TURN        257    259       {ECO:0000244|PDB:4BN4}.
FT   STRAND      262    264       {ECO:0000244|PDB:4BN4}.
FT   HELIX       265    273       {ECO:0000244|PDB:4BN4}.
FT   TURN        281    283       {ECO:0000244|PDB:4BN4}.
FT   STRAND      286    291       {ECO:0000244|PDB:4BN4}.
FT   HELIX       300    304       {ECO:0000244|PDB:4BN4}.
FT   HELIX       305    311       {ECO:0000244|PDB:4BN4}.
FT   STRAND      313    319       {ECO:0000244|PDB:4BN4}.
FT   HELIX       327    330       {ECO:0000244|PDB:4BN4}.
FT   HELIX       331    333       {ECO:0000244|PDB:4C7B}.
FT   STRAND      340    346       {ECO:0000244|PDB:4BN4}.
FT   HELIX       349    353       {ECO:0000244|PDB:4BN4}.
FT   STRAND      359    364       {ECO:0000244|PDB:4BN4}.
FT   HELIX       366    377       {ECO:0000244|PDB:4BN4}.
FT   HELIX       380    391       {ECO:0000244|PDB:4BN4}.
SQ   SEQUENCE   399 AA;  43573 MW;  4BA8BD3AC5FC7901 CRC64;
     MAFWGWRAAA ALRLWGRVVE RVEAGGGVGP FQACGCRLVL GGRDDVSAGL RGSHGARGEP
     LDPARPLQRP PRPEVPRAFR RQPRAAAPSF FFSSIKGGRR SISFSVGASS VVGSGGSSDK
     GKLSLQDVAE LIRARACQRV VVMVGAGIST PSGIPDFRSP GSGLYSNLQQ YDLPYPEAIF
     ELPFFFHNPK PFFTLAKELY PGNYKPNVTH YFLRLLHDKG LLLRLYTQNI DGLERVSGIP
     ASKLVEAHGT FASATCTVCQ RPFPGEDIRA DVMADRVPRC PVCTGVVKPD IVFFGEPLPQ
     RFLLHVVDFP MADLLLILGT SLEVEPFASL TEAVRSSVPR LLINRDLVGP LAWHPRSRDV
     AQLGDVVHGV ESLVELLGWT EEMRDLVQRE TGKLDGPDK
//
